肝硬化门静脉血栓形成诊治新进展

doi:10.3969/j.issn.1672-5069.2024.01.004

摘要/Abstract

关键词: 肝硬化, 门静脉血栓形成, 抗凝治疗, 经颈静脉肝内门体分流术

Key words: Liver cirrhosis, Portal vein thrombosis, Anticoagulant therapy, Transjugular intrahepatic portosystemic shunts

张明. 肝硬化门静脉血栓形成诊治新进展[J]. 实用肝脏病杂志, 2024, 27(1): 11-15.

Zhang Ming. Portal vein thrombosis in cirrhotic patients: the states of the art[J]. Journal of Practical Hepatology, 2024, 27(1): 11-15.

[1] 中华医学会消化病学分会肝胆疾病学组. 肝硬化门静脉血栓管理专家共识(2020年,上海).中华消化杂志, 2020,40(11) : 721-730.
[2] Senzolo M, Garcia-Tsao G, García-Pagán JC. Current knowledge and management of portal vein thrombosis in cirrhosis. J Hepatol,2021,75(2):442-453.
[3] Molvar C, Amin P. Portal vein thrombosis in cirrhosis: Interventional treatment options. Curr Gastroenterol Rep,2021,23(12):24.
[4] Pan J, Wang L, Gao F,et al. Epidemiology of portal vein thrombosis in liver cirrhosis: A systematic review and meta-analysis. Eur J Intern Med, 2022,104:21-32.
[5] Shukla A, Giri S. Portal vein thrombosis in cirrhosis. J ClinExp Hepatol,2022 12(3):965-979.
[6] Anton A, Campreciós G, Pérez-Campuzano V,et al. The pathophysiology of portal vein thrombosis in cirrhosis: Getting deeper into Virchow's triad. J Clin Med,2022,11(3):800.
[7] Stine JG, Wang J, Shah PM,et al. Decreased portal vein velocity is predictive of the development of portal vein thrombosis: A matched case-control study. Liver Int, 2018,38(1):94-101.
[8] Intagliata NM, Argo CK, Stine JG, et al. Concepts and controversies in haemostasis and thrombosis associated with liver disease: Proceedings of the 7th international coagulation in liver disease conference. Thromb Haemost,2018, 118(8):1491-1506.
[9] Driever EG, von Meijenfeldt FA, Adelmeijer J, et al. Nonmalignant portal vein thrombi in patients with cirrhosisconsist of intimal fibrosis with or without a fibrin-rich thrombus. Hepatology, 2022,75:898–911.
[10] Nicoară-Farcău O, Soy G, Magaz M, et al. New insights into the pathogenesis, risk factors, and treatment of portal vein thrombosis in patients with cirrhosis. Semin Thromb Hemost, 2020,46(6):673-681.
[11] Ghabril M, Agarwal S, Lacerda M,et al. Portal vein thrombosis is a risk factor for poor early outcomes after liver transplantation: Analysis of risk factors and outcomes for portal vein thrombosis in waitlisted patients. Transplantation, 2016,100(1):126-33.
[12] Qi X, Dai J, Jia J,et al. Association between portal vein thrombosis and survival of liver transplant recipients: a systematic review and meta-analysis of observational studies. J Gastrointestin Liver Dis,2015,24(1):51-59.
[13] Basaranoglu M. Increased prevalence of portal vein thrombosis in patients with nonalcoholic steatohepatitis-cirrhosis due to increased proinflammatory cytokines releasing from abdominal adipose tissue. Eur J Gastroenterol Hepatol,2020,32(3):458.
[14] Cagin YF, Bilgic Y, Berber , et al. The risk factors of portal vein thrombosis in patients with liver cirrhosis. Exp Ther Med,2019,17(4):3189-3194..
[15] Xu X, Guo X, De Stefano V,et al. Nonselective beta-blockers and development of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis. Hepatol Int,2019,13(4):468-481.
[16] Rugivarodom M, Charatcharoenwitthaya P. Nontumoral portal vein thrombosis: A challenging consequence of liver cirrhosis. J Clin Transl Hepatol,2020,8(4):432-444.
[17] Turon F, Driever EG, Baiges A,et al. Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors. J Hepatol, 2021,75(6):1367-1376.
[18] Sarin SK, Philips CA, Kamath PS, et al. Toward a comprehensive new classification of portal vein thrombosis in patients with cirrhosis. Gastroenterology, 2016,151(4):574-577,e3.
[19] Yerdel MA, Gunson B, Mirza D,et al. Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. Transplantation,2000,69(9):1873-1881.
[20] Bhangui P, Lim C, Levesque E,et al. Novel classification of non-malignant portal vein thrombosis: A guide to surgical decision-making during liver transplantation. J Hepatol, 2019, 71(5):1038-1050.
[21] Sherman CB, Behr S, Dodge JL,et al. Distinguishing tumor from bland portal vein thrombus in liver transplant candidates with hepatocellular carcinoma: the A-VENA criteria. Liver Transpl,2019,25(2):207-216.
[22] Seedial SM, Mouli SK, Desai KR. Acute portal vein thrombosis: Current trends in medical and endovascular management. Semin Intervent Radiol, 2018,35(3):198-202.
[23] Itare VB, Imanirad D, Almaghraby A. Portal cholangiopathy: An uncommon cause of right upper quadrant pain. Cureus, 2020,12(9):e10281.
[24] Rajesh S, Singh S, Philips CA. Transjugular intrahepatic portosystemic shunt in chronic portal vein thrombosis-From routine recommendations to demanding scenarios. Diagnostics (Basel),2022, 12(12):3100.
[25] Yao C, Zhao M, Ibrahim B,et al. Anticoagulation for the treatment of portal vein thrombosis in cirrhosis: A systematic review and Meta-analysis of comparative studies. J Clin Exp Hepatol, 2023, 13(3):404-413.
[26] Chen A, Stecker E, A Warden B. Direct oral anticoagulant use: A practical guide to common clinical challenges. J Am Heart Assoc,2020,9(13):e017559.
[27] O’Shea RS, Davitkov P, Ko CW, et al. AGA clinical practice guideline on the management of coagulation disorders in patients with cirrhosis. Gastroenterology, 2021,161:1615–1627,e1.
[28] EASL clinical practice guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. J Hepatol, 2022,76:1151–1184.
[29] Loffredo L, Pastori D, Farcomeni A,et al. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: A systematic review and Meta-analysis. Gastroenterology, 2017,153(2):480-487,e1.
[30] Koh JH, Liew ZH, Ng GK,et al. Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist for portal vein thrombosis in cirrhosis: A systematic review and meta-analysis. Dig Liver Dis,2022,54(1):56-62.
[31] Northup PG, Garcia-Pagan JC, Garcia-Tsao G,et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology,2021,73(1):366-413.
[32] Sun XY, Wang GC, Wang J,et al. Transjugular intrahepatic portosystemic shunt is effective in patients with chronic portal vein thrombosis and variceal bleeding. Hepatobiliary Pancreat Dis Int,2021,20(2):128-136.
[33] Lyu Y, Qi X, He C,et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut,2018,67(12):2156-2168.
[34] Luo X, Wang Z, Tsauo J,et al. Advanced cirrhosis combined with portal vein thrombosis: A randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology, 2015,276(1):286-293.
[35] Jiang TT, Luo XP, Sun JM,et al. Clinical outcomes of transcatheter selective superior mesenteric artery urokinase infusion therapy vs transjugular intrahepatic portosystemic shunt in patients with cirrhosis and acute portal vein thrombosis. World J Gastroenterol,2017,23(41):7470-7477.

肝硬化门静脉血栓形成诊治新进展

Portal vein thrombosis in cirrhotic patients: the states of the art

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	靳珂珂, 丁惠国. 肝硬化门静脉血栓形成风险监测及抗凝管理^*[J]. 实用肝脏病杂志, 2024, 27(1): 3-6.
[2]	鲁文婷, 张峰. 非肝硬化门静脉系统血栓形成临床管理[J]. 实用肝脏病杂志, 2024, 27(1): 7-10.
[3]	穆玉娟, 吴斐斐, 陈莹. 磁共振增强T1 mapping和IVIM-DWI技术评估乙型肝炎肝硬化患者肝脏储备功能价值研究^*[J]. 实用肝脏病杂志, 2024, 27(1): 68-71.
[4]	宋一凡, 郑帅, 许芸, 唐铁骑. 超声半定量评分结合瞬时弹性成像技术评估乙型肝炎肝硬化并发食管静脉曲张价值研究^*[J]. 实用肝脏病杂志, 2024, 27(1): 72-75.
[5]	李新力, 秦长江, 尹方方. 特利加压素治疗肝硬化并发食管胃静脉曲张破裂出血患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(1): 76-79.
[6]	张迎迎, 魏珂乐, 丁鹤, 郭慧杰, 崔轶, 王昳. 失代偿期肝硬化并发自发性细菌性腹膜炎患者危险因素和PBMC CD36/mTORC1信号通路变化研究^*[J]. 实用肝脏病杂志, 2024, 27(1): 80-83.
[7]	王东君, 张春岩, 晁祥嵩, 李志, 王兴权. 肝硬化合并急性胆囊炎患者手术风险评估^*[J]. 实用肝脏病杂志, 2024, 27(1): 133-136.
[8]	邹涛, 张敏, 杨凡, 王丽, 喻峰. 慢性乙型肝炎和乙型肝炎肝硬化患者PBMCs 信号转导和转录激活因子3及血清可溶性CD30分子水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(6): 855-858.
[9]	田宇, 陈燕, 曹佳非, 周晓倩. 肝硬化并发肝肾综合征患者U-mAl及外周血NLR和血清NGAL水平变化研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 859-862.
[10]	姜亚超, 尹力, 颜状. “改良三明治夹心法”行ESVD术治疗肝硬化并发食管胃静脉曲张患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 863-866.
[11]	刘欢, 陈鹏, 蒯文涛, 徐亮. 肝脏硬度测定、血小板计数/脾厚比值和脾静脉直径预测肝硬化并发食管静脉曲张价值研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 867-870.
[12]	贺梅年, 赵思佳, 田智超, 何秀英, 巴正武. 超声半定量评分结合弹性成像诊断慢性乙型肝炎患者早期肝硬化临床价值分析^*[J]. 实用肝脏病杂志, 2023, 26(6): 871-874.
[13]	杨帆, 张小娟, 李丹, 姜莎莎, 张亮, 唐伟, 赵微. 胃镜下硬化术联合组织胶注射术治疗乙型肝炎肝硬化并发食管胃静脉曲张破裂出血患者1年再出血危险因素分析^*[J]. 实用肝脏病杂志, 2023, 26(6): 875-878.
[14]	周莉, 丁云清, 袁凤英, 陈竹, 冯志伟. 超声造影判断乙型肝炎肝硬化患者肝内占位性病变性质价值研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 903-906.
[15]	刘明, 王金婷, 杨士彦, 杨位轩, 万元春. ESPBD与EST治疗肝硬化合并胆总管结石患者疗效比较^*[J]. 实用肝脏病杂志, 2023, 26(6): 915-918.